Clinical trial
A Phase 3, Multicenter, Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of Peramivir Administered Intravenously in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Serious Influenza
NCT00958776 is registered in ClinicalTrials.gov with BioCryst Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Multicenter, Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of Peramivir Administered Intravenously in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Serious Influenza
- Lead sponsor
- BioCryst Pharmaceuticals
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- November 30, 2009
- Completion date
- October 31, 2013
- Enrollment
- 405 (actual)
- Sites
- 196
Conditions
As the registry lists them; a condition with its own page is linked.